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Abstract
Background: Integrin-linked kinase (ILK) is a ubiquitously expressed protein kinase that has
emerged as one of the points of convergence between integrin- and growth factor-signalling
pathways.
Results: In this study we identify the ILK isoform expressed in five human oesophageal squamous
cell carcinoma cell lines of South African origin as ILK1, and demonstrate its cellular distribution.
ILK expression, although similar in the majority of the cell lines, did show variation. Furthermore,
the ILK expressed was shown to be catalytically functional. The effect of growth factors on ILK
expression was examined. An increase in ILK expression, following EGF and TGFβ1 exposure, was
a trend across all the five oesophageal carcinoma cell lines tested.
Conclusion: These results suggest that growth factor modulation of ILK expression relies on the
internalisation/recycling of growth factor receptors and stimulation of the PI3K pathway, which
may have implications with regards to cell adhesion and tumourigenesis.
Background
While responsiveness to growth factors is central to a host
of normal cellular events, aberrant activity plays a key role
in tumour development [1-3]. Among the numerous
growth factors identified, epidermal growth factor (EGF)
and transforming growth factor-1 (TGFβ1) are key players
in neoplastic progression [2,4]. The action of EGF has
been implicated in malignant transformation in squa-
mous cancers of the bladder, breast and lung [5], whereas
colon, gastric, endometrial, ovarian and cervical malig-
nancies exhibit loss of response to TGFβ1 as a growth
inhibitor [6,7]. Regarding carcinoma of the oesophagus in
particular, reduced TGFβ1 has been correlated with depth
of invasion, lymph node metastasis and poor prognosis
[8].
In normal epithelial cells, appropriate cellular attachment
is necessary for signalling pathways to be elicited [9,10].
More specifically, the response to growth factors can be
potentiated by the integrin class of adhesion receptors
through the integrin-associated protein, integrin-linked
kinase (ILK) [1,7,11].
The ILK protein is a ubiquitously expressed serine/threo-
nine protein kinase that is activated in response to PI3K
stimulation [9,11-17]. Once activated, ILK couples
integrins to downstream signalling pathways that are
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involved in the suppression of apoptosis and in promot-
ing cell cycle progression [9,13,15,18-21]. The functional
significance of ILK in malignancies is highlighted by the
fact that ILK is overexpressed in several human tumours,
including Ewing's sarcoma, primitive neuroectodermal
tumour and medullablastoma [11,22,23]. Furthermore,
ILK has been shown to induce an invasive phenotype in
prostate and brain tumour cell lines [19,24].
Since our focus concerns oesophageal carcinoma, ILK
expression is particularly intriguing since this tumour has
a propensity to invade and metastasise. Carcinoma of the
oesophagus has an extremely high incidence with high
mortality and a poor prognosis [25-27]. It has the widest
variation in incidence by geographical location of any
neoplasm occurring in China, the Transkei region of
South Africa, France and northern Iran [25-27]. In the cell
lines under investigation, EGF is of particular relevance,
stemming from the demonstration that these cell lines
overexpress the EGF receptor [28]. It therefore becomes
necessary to consider the effects of growth factors when
examining the regulatory mechanisms of ILK expression.
This report demonstrates novel data for the expression of
ILK in five human oesophageal carcinoma cell lines and
that this expression is modulated by EGF and TGFβ1.
Results
ILK1 in Human Oesophageal SCC cell lines (HOSCCs)
RT-PCR analysis identified a prominent ILK fragment of
1360 bp in all the HOSCC cell lines (Figure 1), corre-
sponding to the size of ILK in published data [1,29]. Fur-
thermore, RFLP analysis showed the ILK, expressed by the
HOSCCs, to be digested by BamH1 to two fragments of
approximately 823 and 536 bp respectively (Figure 2A).
Digestion of the ILK fragment did not occur with the Hin-
cII restriction enzyme (Figure 2B) confirming that these
oesophageal SCC cell lines only express the ILK1 isoform.
ILK protein expression under standard culture conditions
Immunoblotting analysis of Triton X-100 based extrac-
tions revealed a single 59 kDa band present in the mem-
brane-associated fractions from the HOSCCs (Figure 3A).
These results compare favourably with data obtained for
ILK expression in colon and prostate carcinomas, as well
as neuroblastoma, and melanoma cells [1,12,30], and
therefore represent the first demonstration of ILK expres-
sion in human squamous carcinoma cell lines of the
oesophagus.
Densitometric analysis revealed that ILK expression levels
were comparatively similar across the WHCO3, WHCO5
and SNO cell lines (per μg of total cellular protein
extracted). However, differences in expression were
observed for cell lines WHCO1 (1.3 fold higher) and
WHCO6 (1.5 fold lower) than the average (Figure 3B).
Localisation of ILK in HOSCCs
In addition to the expected cytoplasmic localisation, a
large proportion of the cellular ILK was found to be
present in the nucleus (Figure 4A–E, red arrows). Both
RT-PCR analysis of ILK expression in HOSCCs Figure 1
RT-PCR analysis of ILK expression in HOSCCs. RT-
PCR was performed using specific primers co-amplifying ILK1 
and ILK2. PCR products in the HOSCC cell lines WHCO1, 
WHCO3, WHCO5, WHCO6 and SNO separated on 2% 
agarose gels and stained with ethidium bromide. (A) An ILK 
band of 1360 bp was amplified across all five cell lines. 1 kb 
ladder in lane 1.
 CO1   CO3  CO5 CO6  SNO 
-1360
Determination of ILK isoform/s in HOSCCs Figure 2
Determination of ILK isoform/s in HOSCCs. Amplified cDNA fragments were digested with either BamH1 (B) or HincII 
(H) restriction enzymes. Non-digested (N) and digested fragments (B, H) were separated on 2% agarose gel electrophoresis 
and stained with ethidium bromide. (A) BamH1 restriction analysis produced two fragments of 823 and 536 bp respectively 
whereas (B) HincII restriction analysis did not digest the 1360 bp ILK fragment. 1 kb ladder in lane 1.
bp 
-1360 
-823 
-536
bp 
-1360 
(A)                   B       N       B       N      B         N      B       N          (B)            H      N     H      N     H      N      H     N      H     N 
              1        2        3       4        5         6        7        8        9                       1      2      3       4      5       6      7       8      9     10     11  Cancer Cell International 2006, 6:12 http://www.cancerci.com/content/6/1/12
Page 3 of 12
(page number not for citation purposes)
nuclear and cytoplasmic localisation of ILK was corrobo-
rated by immunoblotting extracts of nuclear fractions
(Figure 5, example WHCO6 and WHCO3). More typical
of cytoplasmic ILK localisation was the observed focal
adhesion association of ILK, implicating ILK in cell-ECM
interactions (Figure 4A–E, yellow arrows). When analysed
in conjunction with the β1 integrin subunit, it was noted
that both ILK and the β integrin subunit followed a simi-
lar focal adhesion distribution pattern (figure 4G and 4H,
yellow arrows) supporting the notion that ILK plays a sig-
nificant role in cell-ECM adhesion processes.
ILK expression following time-dependent exposure to EGF 
in oesophageal SCC cell lines
Having established baseline data for ILK in HOSCC the
effect of growth factors on ILK protein expression was
examined. Exposure to EGF generally produced an
increase in ILK expression in the five oesophageal carci-
noma cell lines, although there was some variation in the
magnitude of the increases. Similarities in ILK expression
levels were observed between the WHCO3, WHCO5 and
WHCO6 cell lines, whereas ILK levels in the WHCO1 and
SNO cell line each responded somewhat differently to
growth factor treatment (Figure 6A).
In the case of the WHCO1 cell line, highest ILK expression
was noted after 1 hour EGF exposure where a fold increase
of 1.8 fold was observed. This increase was maintained
though to 24 hours where a 1.3 fold increase in ILK
expression was seen. The WHCO3, WHCO5 and WHCO6
cell lines produced similar trends in ILK expression fol-
lowing time dependent exposure to EGF. ILK expression
levels continued to increase following increased exposure
to EGF in the WHCO3 cell line, reaching a substantial
increase of 4.5 fold after 24 hours EGF treatment. Simi-
larly, in the WHCO5 and WHCO6 cell lines, a large
increase was observed following 0.5 hours EGF treatment
of 3 and 2.7 fold respectively. Increased ILK expression
levels remained constant and highest ILK expression was
observed following 24 hours EGF exposure of 3.4 and 2.9
fold respectively (figure 6B).
The SNO cell line was somewhat outstanding in that this
cell line elicited greatest ILK expression of 2.2 fold follow-
ing 0.5 hours EGF exposure. Thereafter, a less substantial
increase was noted at 1 hour of 1.5 fold, which was main-
tained through to 24 hours (Figure 6B).
ILK expression following time-dependent exposure to 
TGFβ1 in oesophageal SCC cell lines
Following treatment with TGFβ1 produced an overall an
increase in ILK expression (immunoblotting), not unlike
the effect of EGF. However, variations were noted in the
WHCO1 and SNO cell lines where fluctuations in ILK
expression were observed (Fig. 7A). After 0.5 hours ILK
expression increased by 2.5 and 2.7 fold in the WHCO1
and SNO cell lines respectively. By 1 hour ILK expression
in WHCO1 cells returned to levels comparative to
untreated fractions, whereas in SNO ILK expression had
decreased. By 3 hours however, an overall increase of 1.4
(WHCO1) and 2 (SNO) had been attained. Surprisingly,
a reduction was observed at 6 hours in comparison to the
untreated fraction, 0.7 and 0.4 fold below for the WHCO1
and SNO cell lines respectively. Thereafter ILK expression
levels increased after exposure for 24 hours by 1.1
(WHCO1) and 1.9 (SNO) fold (Figure 7B).
The WHCO3, WHCO5 and WHCO6 cell lines demon-
strated a similar trend in increasing ILK expression in
response to TGFβ1 treatment. The WHCO3 cell line pro-
duced a substantial increase in ILK expression reaching
and maintaining a 7 fold increase over 3 hours exposure.
Surprisingly, exposure to TGFβ1 for 6 hours did not pro-
duce a higher increase in ILK expression, although ILK
expression was still 5.6 fold higher than the untreated
control (Figure 7B). ILK expression continued to decrease
at 24 hours TGFβ1 exposure but still producing a 4.4 fold
increase. Exposure to TGFβ1 for 0.5 hours in the WHCO5
and WHCO6 cell lines caused an increase in ILK expres-
sion of 2.5 and 2.4 fold respectively, which was main-
ILK expression under standard conditions Figure 3
ILK expression under standard conditions. (A) Mem-
brane associated cell lysates were resolved on 10% SDS-
PAGE gels, blotted onto nitrocellulose filters and probed 
with anti-ILK antibody (1:1500). Each cell line produced a sin-
gle anti-ILK reactive band of 59 kDa that varied in concentra-
tion. (B) Subsequent densitometric analysis utilising 
Labworks™ Image Acquisition and Analysis software (Lab-
works version 4.5) was performed on all cell lines to deter-
mine the relative levels of ILK expression under standard 
tissue culture conditions.
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tained continued to increase reaching 2.8 (WHCO5) and
4 (WHCO6) fold. ILK expression reached peak levels at 6
hours of 4.3 (WHCO5) and 6.4 (WHCO6) fold (Figure
7B). By 24 hours, ILK levels decreased producing a much
reduced increase of 2.9 (WHCO5) and 1.9 (WHCO6)
fold.
Immunfluorescence localisation of ILK Figure 4
Immunfluorescence localisation of ILK. Under standard tissue culture conditions ILK localised to both cytoplasmic and 
nuclear compartments (red arrows). ILK was detectable at focal adhesions (yellow arrows) in the (A) WHCO1, (B) WHCO3, 
(C) WHCO5, (D) WHCO6 and (E) SNO cell lines. ILK was stained utilising an anti-ILK antibody (1:500). Bar, 10 μm.
   (A) WHCO1 (B) WHCO3                        (C) WHCO5
   (D) WHCO6 (E) SNO       (F) Control
   (G) β1 integrin (WHCO6)  (H) β1 integrin (SNO)Cancer Cell International 2006, 6:12 http://www.cancerci.com/content/6/1/12
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EGF and TGFβ1 downregulate ILK Activity in HOSCCs
Having determined the presence of ILK, it became neces-
sary to assess the functionality of the catalytic domain.
Furthermore, since growth factors were shown to stimu-
late ILK expression the effect of these growth factors on
ILK activity was of interest. In this instance, myelin basic
protein (MBP), which contains a β1 integrin peptide, was
used to demonstrate the basal kinase activity of ILK. The
five cell lines displayed a range of activities with the
WHCO5 cell line exhibiting highest ILK activity (higher
by 2 fold than average ILK activity) and the WHCO3 dem-
onstrating much lower activity levels (2.5 fold lower than
average) (Figures 8A and 8B). The remaining three cell
lines (WHCO1, WHCO6 and SNO) produced a similar
pattern of activity. These data demonstrated that ILK activ-
ity levels show some variation across the five moderately
differentiated oesophageal SCC cell lines examined.
Interestingly, it was observed that treatment of cell cul-
tures with 10 ng/ml EGF and TGFβ1 for a period of 24
hours resulted in a decline in ILK kinase activity of 1 to 3
fold in cell lines WHCO1, WHCO6 and SNO (established
by densitometry, figure 8C and 8D). However, paradoxi-
cal results were obtained in the case of the WHCO5 cell
line, where treatment with TGFβ1 reduced ILK activity,
whereas EGF augmented ILK activity. The addition of
growth factors had the greatest effects on the WHCO3
line, which showed a dramatic increase in activity to both
EGF (3 fold) and, TGFβ1 (3.5 fold). Although TGFβ1
treatment had a similar effect to that of EGF, its effect on
ILK activity was more profound. When considering
growth factor effects upon ILK expression and activity, it
became apparent that increased ILK expression induced
by growth factors did not necessarily imply a similar
response in ILK activity.
Discussion
Despite data being available for ILK expression in a variety
of tumour types (prostate, breast, and colorectal,
[11,12,19,22,23], the same cannot be said for carcinoma
of the oesophagus. Moreover, since the cell lines exam-
ined here are known to overexpress the EGF receptor [28],
determining the effects of growth factors on ILK expres-
sion is pertinent to our understanding of the adhesion/
signalling role of ILK in the moderately differentiated
class of oesophageal SCC.
The two mRNA isoforms of ILK (ILK1 and ILK2), share
similar structural and functional properties but, whereas
ILK1 is expressed in all normal tissues, ILK2 has only been
identified in two highly metastatic fibrosarcoma and
melanoma cell lines [1]. Here we established that the ILK1
isoform predominates in HOSCCs, and is catalytically
functional. In addition to ILK demonstrating a typical
focal adhesion localisation, ILK was also observed in the
nuclear and cytoplasmic compartments. The nuclear dis-
tribution of ILK is somewhat surprising but has been dem-
onstrated previously and may be attributable to an
impairment of the ILK association with either PINCH or
caveolin [21,23]. These data therefore provided the base-
line for examining the effects of growth factor on ILK pro-
tein expression in HOSCC cells.
With the exception of the WHCO1 and WHCO6 cell lines,
the expression levels of ILK were relatively similar among
the WHCO3, WHCO5 and SNO cell lines (see figure 3B).
However, since ILK expression levels were not uniform
across all five HOSCCs, being somewhat higher in the
WHCO1 cell line and lower in the WHCO6 cell line, we
could not consider the observed ILK expression as pecu-
liar to the moderately differentiated oesophageal pheno-
type.
ILK acts as a molecular scaffold during a host of signalling
events, mediating crosstalk between integrins and the
growth factor response [11], thus eliciting downstream
events that impinge upon vital aspects of cellular function
[10,31]. Although many of the signals elicited by ILK are
a direct result of growth factor signalling, the effect of
growth factors on ILK protein expression and kinase activ-
ity has not been considered to any great extent. In these
HOSCCs, the general response of ILK to both EGF and
TGFβ1 treatment was an increase in ILK protein expres-
sion levels over the duration of growth factor exposure
(see figures 6B and 7B). It is likely that this stimulation
occurs via activation of the PI3K pathway, which has been
shown to be activated in response to these growth factors
[32,33]. The only other report of EGF and TGFβ1 effects
on ILK expression, showed stimulation of ILK expression
in a human melanoma cell line following exposure to EGF
and TGFβ1 for 24 and 48 hours [1]. However, since a
rapid response in ILK expression to both EGF and TGFβ1
by most cells has been shown previously [4,34], the
ILK in nuclear fractions Figure 5
ILK in nuclear fractions. Membrane/nuclear cell fractions 
(10 μg/ml) were immunoblotted as before with anti-ILK anti-
body (1:1500). (A) ILK protein expression in the WHCO6 
and WHCO3 cell lines in the cytoplasmic and nuclear frac-
tions.
   CO6  CO3   CO6  CO3
-59kDa
IB: Anti-ILK 
   Cytoplasmic  NuclearCancer Cell International 2006, 6:12 http://www.cancerci.com/content/6/1/12
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ILK is catalytically active in HOSCCs Figure 6
ILK is catalytically active in HOSCCs. ILK was immunoprecipitated using protein A sepharose beads (25 mg). MBP kinase 
assays were performed utilising 10 μCi [γ-32p] ATP and kinase reaction products were resolved on 10% SDS-PAGE subjected 
to autoradiography. (A) MBP phosphorylation in the WHCO1, WHCO3, WHCO5 WHCO6 and SNO cell lines. (B) Semi-
quantitative ILK kinase activity established by densitometry of autoradiograms. The levels of MBP phosphorylated kinase prod-
ucts of WHCO1, WHCO3, WHCO5, WHCO6 and SNO. (C) The effect of 24 hours EGF and TGFβ1 exposure on ILK kinase 
activity in the WHCO1, WHCO3, WHCO5 and SNO cell lines. (D) Semi-quantitative ILK kinase activity established by densi-
tometry of autoradiogams. Results are representative of three independent experiments.
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Effect of EGF on ILK expression over time Figure 7
Effect of EGF on ILK expression over time. (A) Serum starved cells were treated with 10 ng/ml EGF for 0, 0.5, 1, 3 and 6 
hours respectively and membrane associated fractions immunoblotted as before with a anti-ILK antibody (1:1500) in the 
WHCO1, WHCO3, WHCO5, WHCO6 and SNO cell lines. (B) Densitometric analysis of the expression levels of ILK in the 
HOSCCs demonstrated an increased trend in ILK expression, although variations in expression were noted at certain 
instances.
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Effect of TGFβ1 on ILK expression over time Figure 8
Effect of TGFβ1 on ILK expression over time. (A) Serum starved cells were treated with 10 ng/ml TGFβ1 for 0, 0.5, 1, 3 
and 6 hours respectively. Membrane-associated fractions were resolved on 10% SDS-PAGE gels, blotted onto a nitrocellulose 
filter and probed with an anti-ILK antibody (1:1500) in the WHCO1, WHCO3, WHCO5, WHCO6 and SNO cell lines. (B) 
Densitometric analysis revealed that although expression levels of ILK were generally increased across the five HOSCC cell 
lines, fluctuations were observed in the WHCO1 and SNO cell lines.
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present study concentrated on shorter exposure times in
addition to the longer exposure times.
The noted variations in ILK expression among the cell
lines suggest that a receptor recycling mechanism occurs
in response to these growth factors depending on the time
exposure. In the instances where ILK expression decreased
abruptly, the decrease could be attributable to a reduction
in the number of receptors at the membrane as a result of
receptor internalisation [35]. It is widely accepted that,
although EGFR localises primarily at the cell surface, they
constantly recycle through the cell [36]. Furthermore,
rates in recycling can be accelerated as a consequence of
EGF ligand-binding [34,36-43]. It is highly probable that
the noted fluctuations in ILK expression in the WHCO3,
WHCO5 and SNO cell lines are attributed to this receptor
internalisation/recycling process where lowered EGF sig-
nalling occurs as a result of EGFR reduction at the plasma
membrane. A direct consequence being reduced ILK acti-
vated due to reduced PI3K signalling.
Likewise, the receptors of TGFβ1 also undergo recycling
both in the presence and absence of ligand activation
[44]. Although scarce, early reports suggest that internal-
ised receptors are either rapidly replaced or recycled back
to the cell membrane [45,46]. More recently, [46] showed
that in lung epithelial cells TGFβ1 receptors do indeed
recycle and degrade in a clathrin-dependent approach, but
in a manner that is not dependent on ligand stimulation.
It is possible that ligand stimulation may be required in
the case of HOSCCs and the noted fluctuations following
TGFβ1 exposure may be explained by receptor recycling.
To determine whether growth factors induced a similar
response in both ILK expression and activity in HOSCCs,
ILK kinase assays were conducted in the presence of EGF
and TGFβ1. Given that the greatest increase in ILK expres-
sion was noted following 24 hours growth factor expo-
sure, cells were exposed to growth factors for a similar
period of time. With the exception of the WHCO3 cell line
which showed a marked increase in ILK kinase activity,
the general trend was a decline in ILK kinase activity over
the other cell lines following growth factor exposure (see
figure 8D). This data is surprising since [24], have previ-
ously shown that a rapid stimulation of ILK activity by
insulin and PDGF occurred in intestinal epithelial cells.
The substantial increase in ILK activity in the WHCO3 cell
line could be attributed to decreased PTEN since TGFβ1
has been shown to downregulate PTEN mRNA in kerati-
nocytes [47]. In contrast, EGF and TGFβ1 may be stimu-
lating PTEN activity in the WHCO1, WHCO6 and SNO
cell lines. Due to the increased EGFR that have been
reported with regards to the oesophageal SCC lines, one
could also argue that the cell lines WHCO1, WHCO6, and
SNO are at an upper limit of growth factor response. Thus,
growth factor treatment of these cell lines would not elicit
any further cellular responses, a consequence being that
ILK would not be activated, accounting for the low levels
of ILK kinase activity observed in these cell lines. This
speculation is supported by the suggestion that in fibrob-
lasts higher TGFβ1 concentrations results in inhibition of
both cell migration and proliferation [48].
While the cellular expression of ILK in HOSCCs is compa-
rable to that of other cell types, particularly noteworthy is
that ILK expression in HOSCCs appears to be dependent
on the receptor recycling of both the EGF and TGFβ1
receptors. EGF/TGFβ1 has been shown to result in a rapid,
marked increase in ILK expression, and since it is known
that EGFR overexpression occurs in these HOSCCs, it is
plausible that a constitutive increase in ILK expression
exists in these HOSCCs. A direct consequence of EGF/
TGFβ1 stimulation of the ILK pathways could thus be
decreased cellular adhesion due to impaired integrin-
mediated signalling, or a stimulation of mitogenic path-
ways such as MAPK thereby promoting transformation.
Materials and methods
Cell lines
Five South African moderately differentiated human
oesophageal squamous carcinoma cell lines WHCO1,
WHCO3, WHCO5, WHCO6 [28] and SNO [49] were
obtained from the Cell Biology Laboratory, School of
Molecular and Cell Biology, University of the Witwa-
tersrand. Medium was removed and cells washed twice
with pre-warmed (37°C) phosphate buffered saline
(PBS). Cells were harvested using 0.05% (w/v) trypsin
and 0.01% (w/v) EDTA. Cell lines were cultured in 10 cm
Nunc™ tissue culture dishes with Dulbecco's Modified
Eagles Medium (DMEM)/Hams F12 (3:1), supplemented
with 10% Foetal Calf (or bovine) Serum (FCS or FBS).
Cultures were maintained in a humid, 37°C incubator,
5% carbon dioxide (CO2) atmosphere.
ILK amplification by reverse transcription polymerase 
chain reaction (RT-PCR)
Cells were grown to 80% confluence in sterile 10 cm
Nunc™ tissue culture dishes and total RNA isolated using
TRIzol® solution (GibcoBRL). For reverse transcription,
2μg of total RNA was converted into cDNA by MMLV
reverse transcriptase at 37°C for 1.5 hours in a 25μl RT
reaction. Briefly, PCR amplification mixtures contained
cDNA, ILK antisense primer (5'-CTCGAGCTACTTGTCCT-
GCATCTTCTCAAG-3'), sense primer (5'-GAATTCGTAT-
GGACGACATTTTCACTCAGTGC-3') and Expand High
FidelityPLUS Taq (Roche, SA). Thermal cycle conditions
included denaturation at 95°C for 10 minutes, and 30
cycles between 95°C for 15 seconds, 50°C for 1 minute
and a 2 minute extension step at 72°C, followed by a finalCancer Cell International 2006, 6:12 http://www.cancerci.com/content/6/1/12
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elongation at 72°C for 10 minutes. RT-PCR products were
visualised on 2% agarose gels following ethidium bro-
mide (EtBr) staining.
Restriction Fragment Length Polymorphism (RFLP) 
analysis of amplified ILK cDNA
ILK RT-PCR products were purified using a QIAGEN®
QIAquick Purification Kit. Thereafter, restriction digests
were performed by the addition of BamH1 and HincII
restriction enzymes to purified ILK products, and incu-
bated for 1.5 hours at 37°C. Subsequent digestions were
cleared of protein by the addition of phenol/chloroform
and centrifuged at 6000 rpm for 2 minutes and aqueous
phase transferred to a sterile tube. Both 0.7 M EtOH and 3
M NaAc were added and allowed to precipitate DNA for
12 hours at -20°C. Samples were centrifuged at 6000 g for
20 minutes, the supernatant decanted, and the DNA pellet
resuspended in dH2O. Products were visualised on 2%
agarose gels following EtBr staining.
Antibodies
Polyclonal rabbit anti-ILK antibody (Zymed®, USA) and
polyclonal horseradish peroxidase (HRP)-bound anti-
rabbit secondary antibody (Separations, SA) antibodies
were used for immunoprecipitation and immunoblotting
procedures. Polyclonal rabbit anti-ILK antibody and a
fluoroscine isothiocyanate (FITC)-conjugated anti-rabbit
secondary antibody (Chappel, USA) were used for indi-
rect immunofluorescence.
Indirect immunofluorescence
Cells grown to 80% confluency and seeded onto sterile
glass coverslips were fixed with 4% paraformaldehyde and
permeabilised in 0.25% Triton X-100. Exposure to anti-
ILK (1:500) followed by incubation with an anti-rabbit
Fluoroscine Isothiocyanate (FITC)-conjugated anti-rabbit
antibody (1:1000) for ILK. Slides were viewed under a
Zeiss LSM 410 confocal microscope (FITC excitation 490,
emission 525).
Preparation of nuclear cell lysates
Nuclear extractions were performed utilising the Cel-
Lytic™ Nuclear™ Extraction Kit (Sigma, USA), which is
based on a hypotonic buffer treatment followed by a high
salt buffer release of nuclei.
Treatment of oesophageal carcinoma cell lines with EGF 
and TGFβ1
To examine growth factor effects on the WHCO1,
WHCO3, WHCO5, WHCO6 and SNO HOSCC cell lines,
cell cultures were first serum starved for a period of 16
hours. Cells were then treated with either 10 ng/ml EGF or
TGFβ1 for a period of 0.5, 1, 3, 6 and 24 hours respec-
tively. Experiments were repeated on three separate occa-
sions.
Preparation of membrane cell lysates
Cell cultures were washed in PBS containing 20 mM phe-
nyl-methyl-sulphonyl fluoride (PMSF)/Aprotinin (Trasy-
lol® Bayer, SA) stock solution. The cell suspension was
centrifuged at 1000 g for 2 minutes. The supernatant was
decanted, and the cell pellet resuspended in an extraction
buffer (containing 50 mM Tris, 150 mM NaCl, 1 mM
CaCl2, 1 mM MgCl2 and 0.01% aprotinin pH 8.5) and
incubated for 2 hours on ice. Thereafter, samples were
centrifuged at 6000 g for 10 minutes. The resulting cell
lysates were stored at -70°C. Total protein content was
determined using the Bradford assay [50] using the proto-
col from [51].
Immunoblotting
Cell lysates (10 μg) were electrophoresed through 10%
SDS-PAGE gels according to Laemmli, (1970), transferred
to Nitrobind nitrocellulose transfer membrane (MSI,
USA). Nitrocellulose membranes were blocked with a
casein-based blocking buffer (BLOTTO), incubated in
polyclonal anti-ILK antibody (1:1500), followed by incu-
bation in HRP-bound secondary anti-rabbit antibody
(1:2500). Detection was carried out with the Supersignal®
West Pico Chemiluminescent kit. The experiment was per-
formed on three separate occasions.
Immunoprecipitation
Cell lysates (100 μg) were incubated with 2 μg anti-ILK
antibody for 12 hours at 4°C. The resulting immune com-
plexes were incubated for 4 hours at 4°C with protein A
sepharose (Sigma, SA). Immune complexes were captured
by centrifugation and immunoprecipitated ILK resolved
on 10% SDS-PAGE gels, transferred to nitrocellulose filter
and probed with an anti-ILK antibody (1:1500). Detec-
tion was carried out with the Supersignal®  West Pico
Chemiluminescent kit (Pierce, USA).
ILK kinase activity
Immunoprecipitated ILK was incubated in a kinase reac-
tion buffer (50 mM Hepes, 10 mM MnCl2 and 10 mM
MgCl2 pH7), 10 μCi [γ-32P] ATP (Amersham, UK) and 10
μg myelin basic protein (MBP) (Sigma, USA) for 2 hours
at 30°C with gentle agitation. The reaction was termi-
nated by the addition of an equal volume of 2 × laemmli
buffer and incubation at 95°C for 5 minutes. Phosphor-
ylated MBP products were recovered by centrifugation at
6000 g for 10 minutes and resolved on 10% SDS-PAGE,
following Coomassie Blue staining, destaining, and rins-
ing in dH2O and 10% ethanol respectively. Gels were sub-
sequently dried on a slab gel drier SE1160 (Hoefer, San
Francisco). Phosphorylated MBP was detected via autora-
diography.Cancer Cell International 2006, 6:12 http://www.cancerci.com/content/6/1/12
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Densitometric analysis
Densitometric analysis of the western blot and kinase
assay x-ray plates were used for semi-quantitative compar-
ison of ILK protein levels by using the area under the peak.
Expression levels were represented as a percentage of the
maximum per 10 μg of protein. In interpreting the growth
factor data, we considered a 1.2 fold increase (equivalent
to 20%), to be an appreciable increase in ILK expression
levels. All subsequent fold increases are compared to an
untreated control, unless otherwise stipulated.
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